Sorrento Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Sorrento Therapeutics's estimated annual revenue is currently $21.2M per year.
- Sorrento Therapeutics received $150.0M in venture funding in November 2018.
- Sorrento Therapeutics's estimated revenue per employee is $85,802
- Sorrento Therapeutics's total funding is $264.4M.
Employee Data
- Sorrento Therapeutics has 247 Employees.
- Sorrento Therapeutics grew their employee count by -49% last year.
Sorrento Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CSO, Cytimm Therapeutics | Reveal Email/Phone |
2 | VP Finance | Reveal Email/Phone |
3 | SVP Regulatory Affairs | Reveal Email/Phone |
4 | Head Human Resources | Reveal Email/Phone |
5 | EVP & COO | Reveal Email/Phone |
6 | SVP Commercial Operations | Reveal Email/Phone |
7 | VP - Business Development | Reveal Email/Phone |
8 | Head, Clinical Operations | Reveal Email/Phone |
9 | SVP R&D | Reveal Email/Phone |
10 | SVP - General Counsel | Reveal Email/Phone |
Sorrento Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11830M | 8030 | 26% | $2.7B | $83B |
#2 | $1200M | 1330 | -6% | $2.4B | $8.4B |
What Is Sorrento Therapeutics?
Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.
keywords:N/A
$264.4M
Total Funding
247
Number of Employees
$21.2M
Revenue (est)
-49%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sorrento Therapeutics News
Sorrento Therapeutics, Inc, a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory,...
About Sorrento Therapeutics , Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat...
Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $73.7M | 248 | 6% | N/A |
#2 | $49.5M | 250 | N/A | N/A |
#3 | $15M | 250 | 8% | N/A |
#4 | $15M | 251 | 10% | N/A |
#5 | $85M | 251 | 9% | N/A |
Sorrento Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-10-28 | $30.0M | Undisclosed | Article | |
| 2013-10-31 | $34.6M | Undisclosed | Aegis Capital Corp | Article |
| 2014-05-15 | $25.0M | Undisclosed | Aegis Capital Corp | Article |
| 2016-04-12 | $150.0M | Undisclosed | Ally Bridge Group | Article |
| 2016-05-03 | $10.0M | Undisclosed | Yuhan Corporation | Article |
| 2016-06-14 | $150.0M | Undisclosed | Multiple | Article |
| 2016-11-29 | $75.0M | Undisclosed | Hercules Capital, Inc. | Article |
| 2017-04-20 | $43.5M | Undisclosed | Cantor Fitzgerald & Co | Article |
| 2018-11-09 | $150.0M | Undisclosed | Oaktree Capital Management | Article |